However, tamoxifen-resistant tumors eventually emerged from minimal residual disease within the tumor beds in both PDX models after a period of discontinued tamoxifen treatment (Fig. 4, D and E), recapitulating another important phenomenon associated with the clinical progression of aggressive ER+ breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.